Focal high-dose-rate brachytherapy: A dosimetric comparison of hemigland vs. conventional whole-gland treatment

Brachytherapy

Volumn 12, Issue 5, 2013, Pages 434-441

  Kamrava, Mitchell ^a   Chung, Melody P ^a   Kayode, Oluwatosin ^a   Wang, Jason ^a   Marks, Leonard ^a   Kupelian, Patrick ^a   Steinberg, Michael ^a   Park, Sang June ^a   Demanes, D Jeffrey ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Brachytherapy; Focal therapy; Prostate

Indexed keywords

ALGORITHM; ARTICLE; BLADDER; BRACHYTHERAPY; BRACHYTHERAPY IMPLANT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DOSIMETRY; FOLEY BALLOON CATHETER; HUMAN; INTERMETHOD COMPARISON; MALE; MODEL; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; RECTUM; RISK FACTOR; SIMULATION; TREATMENT PLANNING; URETHRA;

BRACHYTHERAPY; FOCAL THERAPY; PROSTATE;

BRACHYTHERAPY; DOSE-RESPONSE RELATIONSHIP, RADIATION; FOLLOW-UP STUDIES; HUMANS; MALE; ORGANS AT RISK; PROSTATIC NEOPLASMS; RADIOMETRY; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, HIGH-ENERGY; RECTUM; TIME FACTORS; URINARY BLADDER;

EID: 84883561137     PISSN: 15384721     EISSN: 18731449     Source Type: Journal    
DOI: 10.1016/j.brachy.2012.09.002     Document Type: Article

References (43)

1. Cancer Prevention and Control: Cancer among men. 2011. Available at: Accessed March 21,2012. http://www.cdc.gov/cancer/dcpc/data/men.htm.
2. Wilt T.J., Brawer M.K., Barry M.J., et al. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): Design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials 2009, 30:81-87.
3. Bill-Axelson A., Holmberg L., Ruutu M., et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011, 364:1708-1717.
4. Sanda M.G., Dunn R.L., Michalski J., et al. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008, 358:1250-1261.
5. Klotz L., Zhang L., Lam A., et al. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010, 28:126-131.
6. Langley S., Ahmed H.U., Al-Qaisieh B., et al. Report of a consensus meeting on focal low dose rate brachytherapy for prostate cancer. BJU Int 2012, 109:7-16.
7. Ahmed H.U., Freeman A., Kirkham A., et al. Focal therapy for localized prostate cancer: A phase I/II trial. J Urol 2011, 185:1246-1254.
8. Muto S., Yoshii T., Saito K., et al. Focal therapy with high-intensity-focused ultrasound in the treatment of localized prostate cancer. Jpn J Clin Oncol 2008, 38:192-199.
9. Lambert E.H., Bolte K., Masson P., et al. Focal cryosurgery: Encouraging health outcomes for unifocal prostate cancer. Urology 2007, 69:1117-1120.
10. Onik G., Vaughan D., Lotenfoe R., et al. The "male lumpectomy": Focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up. Urol Oncol 2008, 26:500-505.
11. Ellis D.S., Manny T.B., Rewcastle J.C. Focal cryosurgery followed by penile rehabilitation as primary treatment for localized prostate cancer: Initial results. Urology 2007, 70(Suppl. 6):9-15.
12. Truesdale M.D., Cheetham P.J., Hruby G.W., et al. An evaluation of patient selection criteria on predicting progression-free survival after primary focal unilateral nerve-sparing cryoablation for prostate cancer: Recommendations for follow up. Cancer J 2010, 16:544-549.
13. Onik G., Narayan P., Vaughan D., et al. Focal "nerve-sparing" cryosurgery for treatment of primary prostate cancer: A new approach to preserving potency. Urology 2002, 60:109-114.
14. Bahn D.K., Silverman P., Lee F., et al. Focal prostate cryoablation: Initial results show cancer control and potency preservation. JEndourol 2006, 20:688-692.
15. Lindner U., Weersink R.A., Haider M.A., et al. Image guided photothermal focal therapy for localized prostate cancer: Phase I trial. J Urol 2009, 182:1371-1377.
16. Lindner U., Lawrentschuk N., Weersink R.A., et al. Focal laser ablation for prostate cancer followed by radical prostatectomy: Validation of focal therapy and imaging accuracy. Eur Urol 2010, 57:1111-1114.
17. Colin P., Estevez J.P., Betrouni N., et al. Therapie photodynamique et cancer de la prostate. Prog Urol 2011, 21:85-92.
18. Rogers C.L., Alder S.C., Rogers R.L., et al. High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol 2012, 187:109-116.
19. Demanes D.J., Martinez A.A., Ghilezan M., et al. High-dose-rate monotherapy: Safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2011, 81:1286-1292.
20. Ahmed H.U., Akin O., Coleman J.A., et al. Transatlantic Consensus Group on active surveillance and focal therapy for prostate cancer. BJU Int 2012, 109:1636-1647.
21. Bachand F., Martin A.G., Beaulieu L., et al. An eight-year experience of HDR brachytherapy boost for localized prostate cancer: Biopsy and PSA outcome. Int J Radiat Oncol Biol Phys 2009, 73:679-684.
22. Morton G., Loblaw A., Cheung P., et al. Is single fraction 15 Gy the preferred high dose-rate brachytherapy boost dose for prostate cancer?. Radiother Oncol 2011, 100:463-467.
23. Crook J., Malone S., Perry G., et al. Postradiotherapy prostate biopsies: What do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 2000, 48:355-367.
24. Crook J.M., Malone S., Perry G., et al. Twenty-four-month postradiation prostate biopsies are strongly predictive of 7-year disease-free survival: Results from a Canadian randomized trial. Cancer 2009, 115:673-679.
25. Mark R.J., White D., Akins R. Interstitial high-dose-rate (HDR) brachytherapy as monotherapy for early stage prostate cancer: Median 8 year results in 321 patients. Int J Radiat Oncol Biol Phys 2011, 81:S14.
26. Ghadjar P., Keller T., Rentsch C.A., et al. Toxicity and early treatment outcomes in low- and intermediate-risk prostate cancer managed by high-dose-rate brachytherapy as a monotherapy. Brachytherapy 2009, 8:45-51.
27. Grills I.S., Martinez A.A., Hollander M., et al. High-dose-rate brachytherapy as prostate cancer monotherapy reduces toxicity compared to low dose rate palladium seeds. J Urol 2004, 171:1098-1104.
28. Hoskin P., Rojas A., Lowe G., et al. High-dose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys 2012, 82:1376-1384.
29. Barkati M., Williams S.G., Foroudi F., et al. High-dose-rate brachytherapy as a monotherapy for favorable-risk prostate cancer: A phase II trial. Int J Radiat Oncol Biol Phys 2012, 82:1889-1896.
30. Martinez A.A., Demanes J., Vargas C., et al. High-dose-rate prostate brachytherapy: An excellent accelerated-hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 2010, 33:481-488.
31. Martin T., Baltas D., Kurek R., et al. 3-D conformal HDR brachytherapy as monotherapy for localized prostate cancer. A pilot study. Strahlenther Onkol 2004, 180:225-232.
32. Yoshioka Y., Konishi K., Oh R.J., et al. High-dose-rate brachytherapy without external beam irradiation for locally advanced prostate cancer. Radiother Oncol 2006, 80:62-68.
33. Ghilezan M., Martinez A., Gustafson G., et al. High-dose-rate brachytherapy as monotherapy delivered in two fractions within one day for favorable/intermediate-risk prostate cancer: Preliminary toxicity data. Int J Radiat Oncol Biol Phys 2012, 83:927-932.
34. Demanes D.J., Gilhezan M., Schour L., et al. High-dose-rate brachytherapy (HDR-BT) as monotherapy for favorable prostate cancer: Excellent 5-year control rates and low toxicity. Int J Radiat Oncol Biol Phys 2007, 69:S83.
35. Ghilezan M., Vargas C., Gustafson G., et al. HDR vs. LDR (Pd103 permanent implants) brachytherapy as monotherapy for prostate cancer: Timing to onset and predictors of erectile dysfunction. Int JRadiat Oncol Biol Phys 2004, 60:S442.
36. Mark R.J., Akins R.S., Anderson P.J. Interstitial high-dose-rate (HDR) brachytherapy as monotherapy for early stage prostate cancer: Areport of 206 cases. Int J Radiat Oncol Biol Phys 2007, 69:S329.
37. Yamada Y., Bhatia S., Zaider M., et al. Favorable clinical outcomes of three-dimensional computer-optimized high-dose-rate prostate brachytherapy in the management of localized prostate cancer. Brachytherapy 2006, 5:157-164.
38. Nguyen P.L., Chen M.H., Zhang Y., et al. Updated results of magnetic resonance imaging guided partial prostate brachytherapy for favorable risk prostate cancer: implications for focal therapy. J Urol 2012 Oct, 188(4):1151-1156.
39. Seo P.H., D'Amico A.V., Clark J.A., et al. Assessing a prostate cancer brachytherapy technique using early patient-reported symptoms: Apotential early indicator for technology assessment?. Clin Prostate Cancer 2004, 3:38-42.
40. Yamada Y., Rogers L., Demanes D.J., et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 2012, 11:20-32.
41. Albert M., Tempany C.M., Schultz D., et al. Late genitourinary and gastrointestinal toxicity after magnetic resonance image-guided prostate brachytherapy with or without neoadjuvant external beam radiation therapy. Cancer 2003, 98:949-954.
42. Vainshtein J.M., Abu-Isa E., Olson K.B., et al. Randomized phase II trial of urethral sparing intensity modulated radiation therapy in low-risk prostate cancer: Implications for focal therapy. Radiat Oncol 2012, 7:82.
43. Zelefsky M.J., Levin E.J., Hunt M., et al. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70:1124-1129.